Ozempic Butt: Drugs That Cause It and Treatments That Help

What Exactly Is Ozempic Butt?

Ozempic butt refers to visible deflation and sagging of the gluteal region that accompanies significant weight loss on GLP-1 receptor agonist medications. The term gained traction on social media in 2023 and has since entered clinical conversations about body-composition side effects of anti-obesity pharmacotherapy.

Why the Buttocks Are Especially Affected

The gluteal region stores a large proportion of subcutaneous fat, particularly in women. When GLP-1 drugs suppress appetite and reduce caloric intake by 20 to 35%, the body draws on these fat depots rapidly [2]. Subcutaneous gluteal fat acts as structural padding. Once it shrinks, the overlying skin, which may have lost collagen and elastin during years of adipose expansion, cannot retract fast enough. The result is a flat, drooping contour that patients describe as looking "deflated."

The Role of Lean Mass Loss

Body-composition data from the STEP 1 trial (N=1,961) showed that participants on semaglutide 2.4 mg lost an average of 14.9% total body weight at 68 weeks, but roughly 39% of that loss came from lean mass rather than fat [1]. Lean mass includes skeletal muscle in the gluteal complex (gluteus maximus, medius, and minimus). Losing both the fat padding and the underlying muscle volume accelerates the deflated appearance. A 2024 sub-analysis published in Nature Medicine confirmed that dual-agonist tirzepatide produces a similar lean-mass-to-fat-loss ratio at higher doses [3].

Who Is Most Vulnerable

Patients over age 50, those with a starting BMI above 40, and individuals who do not perform resistance exercise face the greatest risk. Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has noted: "The patients who come in most distressed about changes in body shape are often those who lost weight very quickly on maximum doses without any structured exercise plan" [4]. Age-related decline in skin elasticity compounds the problem, making older patients particularly susceptible to visible contour changes.

Drugs That Cause Ozempic Butt

The medications most clearly linked to gluteal volume loss all belong to the incretin-based drug class, though other weight-loss agents carry the same risk when they produce rapid, large-magnitude fat loss.

GLP-1 Receptor Agonists

Semaglutide is the prototype. In the STEP 3 trial, participants receiving semaglutide 2.4 mg with intensive behavioral therapy lost 16.0% of body weight at 68 weeks [5]. That magnitude of loss, roughly 35 to 45 pounds for many patients, almost guarantees visible skin laxity in fat-dense areas. Liraglutide (Saxenda) produces more modest weight loss (about 8% at one year in the SCALE trial, N=3,731), so the gluteal effects tend to be less dramatic but still present in patients who respond strongly [6].

Dual GIP/GLP-1 Agonists

Tirzepatide (Mounjaro, Zepbound) has produced the largest weight-loss numbers in the GLP-1 drug class. The SURMOUNT-1 trial (N=2,539) reported 22.5% mean weight loss at the 15 mg dose over 72 weeks [7]. That degree of fat reduction over a relatively short period creates significant skin redundancy in the buttocks, abdomen, and upper arms. Anecdotal reports from plastic surgeons suggest tirzepatide patients are presenting for body-contouring consultations at higher rates than semaglutide patients, likely because of the larger total weight loss.

Older Anti-Obesity Medications

Phentermine-topiramate (Qsymia) and naltrexone-bupropion (Contrave) produce 5 to 10% weight loss in clinical trials [8]. While less dramatic, patients who combine these medications with caloric restriction below 1,200 kcal/day can still develop gluteal deflation. The mechanism is the same: rapid subcutaneous fat depletion outpacing skin retraction.

Medications That Worsen the Appearance

Systemic corticosteroids (prednisone, dexamethasone) redistribute fat away from peripheral depots, including the buttocks, toward central and facial stores. Patients on concurrent GLP-1 therapy and corticosteroids for inflammatory conditions may notice disproportionate gluteal volume loss. Thiazolidinediones (pioglitazone), by contrast, promote subcutaneous fat deposition and have been observed to partially offset peripheral fat loss in some diabetic patients on GLP-1 drugs, though this is not a recommended clinical strategy [9].

Why GLP-1 Drugs Cause Disproportionate Fat Loss

GLP-1 receptor agonists reduce appetite through hypothalamic signaling and slow gastric emptying, leading to a sustained caloric deficit of 500 to 700 kcal/day in most patients [2]. The body does not choose where to burn fat.

Genetics and Fat Distribution

Fat-loss patterns are largely genetically predetermined. Women with gynoid fat distribution (pear-shaped) store more fat in the hips and buttocks and lose it from these areas preferentially during energy deficit. A genome-wide association study published in Nature Genetics identified over 200 loci associated with regional fat distribution, confirming that pharmacologic weight loss cannot target specific depots [10].

Caloric Deficit Magnitude Matters

The speed of weight loss correlates directly with skin laxity severity. A 2023 review in Obesity Reviews found that patients losing more than 1 kg per week had significantly higher rates of skin redundancy requiring surgical correction compared to those losing 0.5 kg per week [11]. GLP-1 drugs at maximum doses often push weight loss beyond the 1 kg/week threshold in the first three to six months.

Protein Insufficiency Amplifies Muscle Loss

Many patients on GLP-1 drugs eat fewer than 60 g of protein daily due to appetite suppression and early satiety. The American Society for Metabolic and Bariatric Surgery (ASMBS) recommends a minimum of 60 to 80 g/day for bariatric patients, and emerging consensus suggests 1.2 to 1.6 g/kg/day for patients on GLP-1 therapy to preserve lean mass [12]. Inadequate protein intake accelerates skeletal muscle catabolism in the gluteal region, worsening both the functional and cosmetic outcome.

How Ozempic Butt Is Diagnosed

There is no formal diagnostic code for ozempic butt. The assessment is clinical, based on patient-reported dissatisfaction and physical examination findings.

Clinical Evaluation

Physicians assess skin laxity using pinch tests and visual grading scales adapted from post-bariatric body-contouring literature. The Pittsburgh Rating Scale, originally developed for massive weight-loss patients, grades excess skin from 0 (normal) to 3 (severe) across body regions including the buttocks [13]. A score of 2 or higher in the gluteal region typically prompts referral for body-contouring consultation.

Body Composition Testing

Dual-energy X-ray absorptiometry (DEXA) quantifies regional fat and lean mass changes. A DEXA scan showing greater than 25% lean mass as a proportion of total weight lost may indicate suboptimal body composition changes requiring intervention [1]. Bioelectrical impedance analysis (BIA) is more accessible but less precise for regional measurements.

Pharmacologic Strategies to Prevent or Reduce Ozempic Butt

Adjusting the drug regimen itself is the first-line approach. This does not mean stopping therapy, but rather optimizing dose, speed of titration, and adjunctive medications.

Slower Dose Titration

Standard semaglutide titration moves from 0.25 mg to 2.4 mg over 16 to 20 weeks. Extending this to 24 to 32 weeks slows the rate of weight loss and gives skin and soft tissue more time to adapt. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity supports individualized titration based on tolerability and patient goals [14].

Dose Plateau Strategy

Some clinicians hold patients at a mid-range dose (e.g., semaglutide 1.0 mg or tirzepatide 7.5 mg) once they reach a 10 to 12% weight loss, rather than pushing to maximum dose. This allows the body to "catch up" with skin retraction before resuming dose escalation. Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has described this as "giving the skin a chance to remodel before the next wave of fat loss" [15].

Testosterone and Anabolic Considerations in Men

Hypogonadal men on GLP-1 therapy face compounded muscle loss. Testosterone replacement therapy (TRT) at physiologic doses (100 to 200 mg testosterone cypionate weekly) has been shown to preserve lean mass during caloric restriction [16]. For men with documented low testosterone (total T <300 ng/dL) who are losing excessive lean mass on GLP-1 drugs, adding TRT may mitigate gluteal muscle atrophy. This requires monitoring of hematocrit, PSA, and lipids per the American Urological Association (AUA) guidelines [17].

Creatine Monohydrate as an Adjunct

Creatine monohydrate at 3 to 5 g/day supports muscle protein synthesis and may help preserve lean mass during GLP-1 therapy. A meta-analysis of 22 studies (N=721) published in the Journal of the International Society of Sports Nutrition found that creatine supplementation during resistance training increased lean mass gains by 1.4 kg compared to placebo [18]. While not a drug, creatine is the best-studied ergogenic supplement and warrants mention alongside pharmacologic strategies.

Non-Drug Treatments for Ozempic Butt

When the damage is done, or while prevention strategies are underway, several treatment modalities can restore gluteal volume and skin quality.

Resistance Training

Progressive gluteal-focused resistance training is the single most effective non-pharmacologic intervention. Hip thrusts, Romanian deadlifts, and Bulgarian split squats directly load the gluteus maximus and medius. A 2022 randomized trial in Obesity (N=195) demonstrated that patients combining GLP-1 therapy with twice-weekly resistance training retained 2.6 kg more lean mass over 12 months compared to those on drug therapy alone [19]. Training must be progressive, meaning loads increase over time, not static bodyweight exercises.

Protein Optimization

Achieving 1.2 to 1.6 g/kg/day of protein intake requires deliberate planning for patients whose appetite is blunted by GLP-1 drugs. Prioritizing protein at each meal (20 to 30 g per sitting) maximizes muscle protein synthesis. Whey protein supplementation can bridge gaps when whole-food intake is insufficient. The timing of protein relative to resistance training (within 2 hours post-exercise) may offer a small additional benefit for muscle preservation [20].

Injectable Biostimulators

Poly-L-lactic acid (Sculptra) injections stimulate collagen production in treated areas. When injected into the gluteal region, Sculptra can restore volume gradually over 2 to 3 treatment sessions spaced 4 to 6 weeks apart. A 2021 retrospective study in Aesthetic Surgery Journal reported an average 30% improvement in gluteal contour satisfaction scores among patients receiving biostimulator injections for volume loss after weight reduction [21]. Results develop over 3 to 6 months as new collagen forms.

Calcium hydroxylapatite (Radiesse) works through a similar biostimulatory mechanism. Hyperdilute Radiesse injections have gained popularity for skin tightening and volume restoration in the buttocks, though large controlled trials specific to post-GLP-1 patients are still lacking.

Radiofrequency and Ultrasound Skin Tightening

Non-invasive devices like radiofrequency (RF) microneedling (Morpheus8) and high-intensity focused ultrasound (HIFU) can tighten mild to moderate skin laxity. These treatments heat the dermal and subdermal layers, triggering collagen remodeling. A series of 3 to 4 treatments spaced 4 to 6 weeks apart is typical. RF-based treatments show the best evidence for mild laxity (Pittsburgh Rating Scale grade 1), but they cannot correct severe skin redundancy [22].

Surgical Body Contouring

For patients with severe gluteal ptosis and skin excess (Pittsburgh grade 2 to 3), surgical options include lower body lift, gluteal augmentation with fat transfer (Brazilian butt lift), and direct excisional buttock lift. The American Society of Plastic Surgeons (ASPS) reported a 46% increase in body-contouring consultations related to GLP-1 weight loss between 2022 and 2024 [23]. Surgical intervention is typically deferred until weight has been stable for at least 6 months.

When to Worry About Ozempic Butt

Most cases of gluteal deflation are cosmetic concerns rather than medical emergencies. But certain patterns warrant clinical attention.

Signs That Require Medical Evaluation

Rapid onset of bilateral gluteal wasting over 2 to 4 weeks, especially with weakness or difficulty rising from a seated position, could signal a myopathy rather than simple fat loss. Statin co-administration is common in patients on GLP-1 drugs (many have metabolic syndrome), and statin-associated muscle symptoms affect 7 to 29% of users depending on the definition applied [24]. A creatine kinase (CK) level and clinical strength assessment can differentiate drug-induced myopathy from benign fat redistribution.

Functional Concerns

The gluteal muscles are primary hip extensors and stabilizers. Excessive gluteal muscle wasting can impair gait, increase fall risk in older adults, and contribute to lower back pain. Patients reporting difficulty climbing stairs, hip instability, or new-onset low back pain after starting GLP-1 therapy should receive functional assessment and physical therapy referral.

Drugs in Development That May Reduce Body Composition Concerns

Several next-generation anti-obesity agents are being designed or studied with body composition in mind.

Bimagrumab

Bimagrumab is a monoclonal antibody targeting activin type II receptors, promoting skeletal muscle growth while reducing fat mass. A phase 2 trial (N=58) in patients with obesity and type 2 diabetes showed that bimagrumab increased lean mass by 3.6% while reducing fat mass by 20.5% over 48 weeks [25]. Combination studies with GLP-1 agonists are in progress, and the theoretical benefit for preventing ozempic butt is significant: patients could lose fat without the proportional lean mass depletion that drives gluteal deflation.

Retatrutide

Retatrutide, a triple-agonist (GIP/GLP-1/glucagon receptor), produced up to 24.2% weight loss in a phase 2 trial (N=338) at 48 weeks [26]. The glucagon receptor component may preferentially mobilize visceral over subcutaneous fat, potentially sparing some gluteal volume, though this hypothesis requires confirmation in body-composition sub-studies.

Patients on any GLP-1 receptor agonist should have body composition discussed at each dose titration visit, with DEXA scanning considered at baseline and 6 to 12 months for those losing more than 15% of body weight.